In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital

References

• Dupont B. Caspofungin: new echinocandin antifungal agent. J Mycol Med 2002; 12: S20—S24.
   Google Scholar
• Datry A, Thellier M. Echinocandins: a new class of antifungal agents, a new mechanism of action. J Mycol Med 2002; 12: S5–S9.
   Google Scholar
• Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61: 1121–1129.
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Invest Drugs 2001; 10: 269–280.
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Invest Drugs 2001; 10: 1545–1558.
   PubMed Web of Science ®Google Scholar
• Chryssanthou E, Cuenca-Estrella M. Comparison of the Anti-fungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed stan-dard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841–3844.
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45: 327–330.
   PubMed Web of Science ®Google Scholar
• Arikan S, Paetznick V, Rex JH. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimi-crob Agents Chemother 2002; 46: 3084–3087.
   Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245–247.
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echino-candin caspofungin acetate kills growing cells of Aspergillus fumi-gatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001–3012.
   PubMed Web of Science ®Google Scholar
• Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41: 1835–1836.
   Google Scholar
• Douglas CM, Bowman JC, Abruzzo GK, et al. The glucan synthesis inhibitor caspofungin acetate (Cancidas, MK-0991, L-743872) kills Aspergillus fumigatus hyphal tips in vitro and is efficacious against disseminated aspergillosis in cyclophospha-mide-induced chronically leukopenic mice, Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemother-apy, Toronto, Canada, 17–20 September 2000, ASM Press Washington, DC, USA. (Abstract no.1683.)
   Google Scholar
• Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three anti-fungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634–3636.
   Google Scholar
• Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228–2230.
   Google Scholar
• Bartizal K, Motyl M, Hicks P, et al. In vitro susceptibility results and correlation with outcome: Results from the randomized inva-sive candidiasis (ic) study of caspofungin vs. amphotericin B. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 27–30 Septem-ber 2000, ASM Press Washington, DC, USA. (Abstract no. M–1240.)
   Google Scholar
• Ju JY, Polhamus C, Marr KA, Holland SM, Bennett JE. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata -infected p47phox-/- knockout mice. Antimicrob Agents Chemother 2002; 46: 1240–1245.
   Google Scholar
• Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183–187.
   Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729–5731.
   PubMed Web of Science ®Google Scholar
• Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000; 182: 1791–1795.
   PubMed Web of Science ®Google Scholar
• Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002; 35: E35–E36.
   Google Scholar
• Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310–2318.
   PubMed Web of Science ®Google Scholar
• Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphoter-icin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451–457.
   PubMed Web of Science ®Google Scholar
• Chocarro MA, Gonzalez A, Garcia I. Caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin Infect Dis 2002; 35: 107–108.
   Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029.
   Google Scholar
• Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529–1535.
   PubMed Web of Science ®Google Scholar
• Bernard EM, Ishimaru T, Armstrong D. Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis. In: Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, USA, 15–18 September 2000, ASM Press Washington, DC, USA.
   Google Scholar
• Caillot D. Invasive aspergillosis/therapeutic aspects: caspofungin. J Mycol Med 2002; 12: S18–S19.
   Google Scholar
• Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42: 1985-1989.
   Google Scholar
• Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Anti-microb Agents Chemother 2001; 45: 1854–1859.
   PubMed Web of Science ®Google Scholar
• Larone D. Medically Important Fungi - A Guide to Identification. Washington, DC: ASM Press, 1995.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard NCCLS document M27-A2. Wayne, PA: NCCLS, 2002.
   Google Scholar
• Waldrep TW, Keiser P, Ware A, et al. Failure of intermittent caspofungin therapy to treat fluconazole-resistant mucocutaneous Candida despite apparent in vitro susceptibility. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Che-motherapy, San Diego, CA, USA, 27–30 September 2000, ASM Press Washington, DC, USA. (Abstract no. M–891.)
   Google Scholar
• Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neofor-mans. Antimicrob Agents Chemother 1997; 41: 1957-1960.
   Google Scholar
• Lozano-Chiu M, Nelson PW, Paetznick VL, Rex JH. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J Clin Microbiol 1999; 37: 1625–1627.
   Google Scholar
• Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001; 39: 4387–4389.
   Google Scholar
• Laverdiere M, Restieri C, Habel F. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of E-test and NCCLS reference methods. Int J Antimicrob Agents 2002; 20: 468–471.
   Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950–2956.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47; 2003: 3149–3154.
   Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326–2332.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-suscep-tible and -resistant Candida species. Antimicrob Agents Che-mother 1997; 41: 1612-1614.
   Google Scholar
• Ostrosky-Zeichner L, Matar M, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 27–30 September 2000, ASM Press, Washington, DC, USA. (Abstract no. M–1816.)
   Google Scholar
• St Germain G. Effects of pentamidine alone and in combination with ketoconazole or itraconazole on the growth of Candida albicans. Antimicrob Agents Chemother 1990; 34: 2304–2306.
   Google Scholar
• Uzun 0, Arikan S, Kocagoz S, Sancak B, Unal S. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphoter-icin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000; 38: 101–107.
   Google Scholar